Role of urokinase inhibitors in choroidal neovascularization

Seminars in Ophthalmology

Volumn 21, Issue 1, 2006, Pages 23-27

  Das, Arup ^a   McGuire, Paul ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Choroidal neovascularization; Proteinase; Retinal neovascularization; Urokinase

Indexed keywords

A 6; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; B 428; GELATINASE A; GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; WX UK1; ENZYME INHIBITOR; PLASMA PROTEIN;

ANGIOGENESIS; BASEMENT MEMBRANE; BLOOD VESSEL; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CANCER THERAPY; CELL INVASION; CELL MIGRATION; CELL SURFACE; CLINICAL TRIAL; COLON CANCER; DISEASE COURSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPRESSION VECTOR; EXTRACELLULAR FLUID; GLIOBLASTOMA; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; RETINA NEOVASCULARIZATION; REVIEW; SOLID TUMOR; SUBRETINAL NEOVASCULARIZATION; TUMOR GROWTH; TUMOR VASCULARIZATION; VIRUS GENE; VISCERAL METASTASIS; ANIMAL; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; BLOOD PROTEINS; CELL MOVEMENT; CHOROIDAL NEOVASCULARIZATION; ENZYME INHIBITORS; HUMANS; URINARY PLASMINOGEN ACTIVATOR;

EID: 33646923412     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530500509366     Document Type: Review

References (25)

1. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Progress Retinal Eye Res 2003; 22:721-48.
2. Rabbani SA, Mazar AP. The role of plasminogen activator system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001; 10:393-415.
3. Malchanda N, Schwartz BS. Single chain urokinase augmentation of enzymatic activity upon binding to monocytes. J Biol Chem 1991; 266:14580-4.
4. Rabbani SA, Desjardins J, Bell AW. An amino terminal fragment of urokinase isolated from a prostate cancer cell line mitogenic for osteobalst-like cells. Biochem Biophys Res Commun 1990; 173:1058-64.
5. Blasi R. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993; 15:105-11.
6. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst Hanse et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4:923-8.
7. Stefansson S, Lawrence DA. Old dogs and new tricks, proteases, inhibitors and cell migration. Science STKE 2003; 189:24-6.
8. Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002; 3:932-43.
9. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57:25-40.
10. Mazar AP. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anti-Cancer Drugs 2001; 12:387-400.
11. Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman M. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 1997; 57:3594-9.
12. Li H, Lu H, Griscelli F, Opolon P, Sun LQ, Ragot T, Legand Y, et al. Adenovirus-medyted delivery of a uPA-uPAR antagoinist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther 1998; 5:1105-13.
13. Das A, McGuire PG, Eriqat C, Ober RR, DeJuan E Jr, Willimas GA, McLamore A, Biswas J, Johnson DW. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999; 40:809-13.
14. Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 1999; 117:498-503.
15. McGuire PG, Jones TR, Talarico N, Warren E, Das, A. The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target. Invest Ophthalmol Vis Sci 2003; 44:2736-42.
16. Rakic JM, Lambert V, Munaut C, Bajou K, Peyrollier K, Alvarez-Gonzalez ML, Carmeliet P, Foidart JM, Noel A. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44:1732-9.
17. Das A, Boyd N, Jones TR, Talarico N, McGuire PG. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model. Arch Ophthalmol 2004; 122:1844-9.
18. Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar, AP. Prevention of prostate cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator. Int J Cancer 1995; 63:843-5.
19. Mishima K, Mazar AP, Gown A, Skelly M, Ji XD, Wang XD, Jones TR, Cavenee WK, Huang HJ. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 2000; 97:8484-9.
20. Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 2000; 14:1400-10.
21. Guo Y, Mazar AP, Lebrun JJ, Rabbani SA. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res 2002; 62:4678-84.
22. Boyd DD, Kim SJ, Wang H, Jones TR, Gallick GE. A urokinase-derived peptide A6 increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am J Pathol 2003; 162:619-26.
23. Le Gat, L, Gogat K, Bouquet C, Saint-Geneiz M, Darland D, Van den Berghe L. et al. in vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in mouse model of retinopathy. Gene Ther 2003; 10:2098-103.
24. Koh HJ, Besho K, Cheng L, Bartsch DU, Jones TR, Bergeron-Lynn G, Freeman WR. Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6. Invest Ophthalmol Vis Sci 2004; 45:635-40.
25. van Troostenburg AR, Lee D, Jones TR, Dyck-Jones JA, Silverman MH, Lam GN, Warrington SJ. Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. Int J Clin Pharmacol Ther 2004; 42:253-9.